Fueling
The Future
of Immunotherapy
Rooted in our commitment to deliver a comprehensive, unparalleled cold tumor treatment platform, ImmunoGenesis is building complementary pipeline programs from the bottom up.
Our pipeline programs directly target several key pathology processes that make cold tumors so difficult to treat.
Our programs
| • | Prime an effective T-cell response |
| • | Block checkpoint signals effectively |
| • | Address the suppressive tumor microenvironment |
Pipeline
ISAC, immune-stimulating antibody conjugate; STING, stimulator of interferon genes; TNBC, triple-negative breast cancer.
Clinical Programs
Our lead program, IMGS-001, entered clinical trials in 2023 with the first patient dosed in September. IMGS-001 is a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function.
Our second clinical program, IMGS-101 (evofosfamide), is a hypoxia-reversal agent and primer for enhanced checkpoint inhibition in cold-tumor treatment. Immune T cells typically do not enter hypoxic zones. By reoxygenating the tumor microenvironment, IMGS-101 frees T cells to traffic to the tumor and attack cancerous cells.
Our Platform
The foundation of our vision is a PD-L1/PD-L2 dual-specific inhibitor platform molecule. ImmunoGenesis will be the first company to target PD-L2, a critical regulator of human tumor immunity. Additionally, the antibody may also function as a tumor-specific delivery vehicle and as the base for trifunctional bispecifics, expanding targeting options.
IMGS‑001
Our lead program is IMGS-001. Preclinical data showed that IMGS-001 offered 5 times the response rate in cold tumors compared with currently available immunotherapies. Additionally, IMGS-001 can provide a foundation for add-on therapies.
Development Programs
Our platform presents opportunities to pair with additional programs. Such programs could include creating trifunctional bispecifics.
IMGS-501 is an antibody-conjugated STING agonist transported systemically by our PD-L1/PD-L2 dual-specific inhibitor, allowing greater flexibility in delivery. With IMGS-501, there is no need for direct tumor injection. The antibody-conjugated STING agonist can be effectively delivered intravenously. The antibody then transports STING to all sites of the tumor and to the appropriate cells within the tumor microenvironment.
Stay tuned.
Our Vision
By harnessing cutting-edge science, the ImmunoGenesis pipeline is designed to redefine the cold tumor treatment landscape, re-envision existing immunotherapy treatment approaches, and ultimately, provide necessary treatments for patients with cold tumors.
Learn more